Enanta Was First To File. Pfizer Still Won. The Difference Was One Digit.
The US Federal Circuit affirmed that every claim in Enanta Pharmaceuticals’ patent on a coronavirus protease inhibitor is invalid in Enanta Pharmaceuticals, Inc. v. Pfizer Inc. (Fed. Cir. June 23, 2026). The court said Enanta’s provisional did not disclose the relevant C1 alkyl range, so Pfizer’s April 6, 2021 nirmatrelvir (Paxlovid) presentation was prior art. Paxlovid earned about $19B in 2022.
How this was made
The 30-second read
Why it matters
Because the court held the provisional did not disclose the relevant C1 alkyl variant, Pfizer’s April 2021 public presentation became prior art that anticipates the claims. This is a direct, final legal defeat for the asserted patent scope.
Market read
For traders, the key actionable item is the final appellate affirmance that eliminates the asserted patent’s enforceability, which can reprice IP-dependent biotech risk.
What to watch
The brief focuses on one substituent mismatch; it does not quantify remaining patent families, licensing economics, or pipeline readouts that could offset the invalidated claims.
Background
The article recounts a Federal Circuit decision affirming invalidity of Enanta’s patent claims for a coronavirus protease inhibitor, tied to Pfizer’s nirmatrelvir disclosure.
Ticker impact
Federal Circuit affirmed Enanta’s coronavirus protease inhibitor patent claims are invalid, based on Pfizer’s prior disclosure of nirmatrelvir.
Near-term downside bias for ENTA on legal overhang; longer-term impact depends on remaining IP and pipeline value not discussed here.
The article describes a final appellate outcome (Fed. Cir. affirmance) that directly defeats the asserted patent, which is typically material for biotech IP-driven valuations.
Market effects
Reinforces written-description and first-to-file risk for COVID-era small-molecule IP, potentially increasing diligence scrutiny across antiviral developers.
Limited; primarily affects US-listed biotech sentiment and litigation risk appetite.
Moderate for global pharma IP strategy, but the described event is US patent litigation.
Counterpoint
ENTA’s equity reaction may be muted if investors already priced in the litigation risk or if the company has other unchallenged assets not covered in this article.
Key entities
- companyEnanta Pharmaceuticals
Subject of the patent invalidation described, with the Federal Circuit affirming invalidity of its coronavirus protease inhibitor claims.
- companyPfizer
The defendant whose nirmatrelvir disclosure served as prior art that defeated Enanta’s claims.
- courtUnited States Court of Appeals for the Federal Circuit
Affirmed the district court’s written-description/prior-art ruling on June 23, 2026.
